Successful treatment of atopic dermatitis with complexes of allergen and specific antibodies

Pathogenesis and Management of Acquired Haemophilia.

Hematology (Amsterdam, Netherlands)·2016

The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.

Haemophilia : the official journal of the World Federation of Hemophilia·2007

The use of antibodies to coagulation factors for anticoagulant therapy.

Current medicinal chemistry·2004

Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.

Blood·2001

Hemophilia factor VIII therapy. B- and T-cell tolerance: from basic concepts to clinical practice.

Haematologica·2001

Antigenicity of putative phospholipid membrane-binding residues in factor VIII.

Blood·2001

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Lancet (London, England)·2026

Emerging Evidence Suggests That N-Glycosylation Pathway Perturbation Has a Greater Impact than Microbial Depletion on α-Gal Antigen Biogenesis in Lone Star Tick (Amblyomma americanum) Salivary Glands.

Microorganisms·2026

Indirect Skin Homeostasis Modulation by an Essential Oil Blend in Mice with Insomnia Comorbid Anxiety: Sensitivity of Dermal Fibroblasts to Exogenously Applied Circulating Molecules.

Pharmaceuticals (Basel, Switzerland)·2026

Beyond Psoriasis Skin Clearance: Effects of Bimekizumab and Tildrakizumab on Systemic Inflammation and Immune-Nutrition Status.

Pharmaceuticals (Basel, Switzerland)·2026

The Alleviative Effect of Oral Administration of Lactiplantibacillus plantarum 22A-3 on Allergic Contact Dermatitis in Mice.

Nutrients·2026

Beyond Eosinophilia: A Dual Eosinophil Phenotype Model in Bronchiectasis.

Medicina (Kaunas, Lithuania)·2026

Analysis of Multi-Site Bile Acid Metabolic Profile Reveals an Association Between Bile Acid-FXR Signaling and Visceral Hypersensitivity in Heterotypic Intermittent Stress-Induced IBS.

International journal of molecular sciences·2026

Related Experiment Videos

Successful treatment of atopic dermatitis with complexes of allergen and specific antibodies

Related Concept Videos

Pathogenesis and Management of Acquired Haemophilia.

The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.

The use of antibodies to coagulation factors for anticoagulant therapy.

Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.

Hemophilia factor VIII therapy. B- and T-cell tolerance: from basic concepts to clinical practice.

Antigenicity of putative phospholipid membrane-binding residues in factor VIII.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Emerging Evidence Suggests That N-Glycosylation Pathway Perturbation Has a Greater Impact than Microbial Depletion on α-Gal Antigen Biogenesis in Lone Star Tick (Amblyomma americanum) Salivary Glands.

Indirect Skin Homeostasis Modulation by an Essential Oil Blend in Mice with Insomnia Comorbid Anxiety: Sensitivity of Dermal Fibroblasts to Exogenously Applied Circulating Molecules.

Beyond Psoriasis Skin Clearance: Effects of Bimekizumab and Tildrakizumab on Systemic Inflammation and Immune-Nutrition Status.

The Alleviative Effect of Oral Administration of Lactiplantibacillus plantarum 22A-3 on Allergic Contact Dermatitis in Mice.

Beyond Eosinophilia: A Dual Eosinophil Phenotype Model in Bronchiectasis.

Analysis of Multi-Site Bile Acid Metabolic Profile Reveals an Association Between Bile Acid-FXR Signaling and Visceral Hypersensitivity in Heterotypic Intermittent Stress-Induced IBS.

Related Experiment Videos

Successful treatment of atopic dermatitis with complexes of allergen and specific antibodies

Related Concept Videos

Related Articles